vatalanib has been researched along with gadolinium in 1 studies
Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (gadolinium) | Trials (gadolinium) | Recent Studies (post-2010) (gadolinium) |
---|---|---|---|---|---|
276 | 42 | 98 | 13,838 | 519 | 6,282 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Drevs, J; Dugan, M; Laurent, D; Morgan, B; Steward, WP; Thomas, AL; Unger, C; Vanhoefer, U; Wiedenmann, B | 1 |
1 review(s) available for vatalanib and gadolinium
Article | Year |
---|---|
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Contrast Media; Drug Screening Assays, Antitumor; Gadolinium; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2003 |